APE1-IN-2 (compound AP1) 是一种靶向关键 BER 蛋白无嘌呤/无嘧啶核酸内切酶 1 (APE1) 的 Pt(IV) 前体,具有抗癌活性,可诱导细胞内铂积累并激活 DNA 损伤反应和凋亡 (apoptosis) 信号。
产品编号: MS-Y05947 纯度: 98.28% CAS No.: 2923433-95-6 分子式: C9H12Cl2N4O5Pt 分子量: 522.21
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

APE1-IN-2 (compound AP1) 是一种靶向关键 BER 蛋白无嘌呤/无嘧啶核酸内切酶 1 (APE1) 的 Pt(IV) 前体,具有抗癌活性,可诱导细胞内铂积累并激活 DNA 损伤反应和凋亡 (apoptosis) 信号。

生物实验数据

生物活性 APE1-IN-2 (compound AP1) is a Pt(IV) prodrug targeting the key BER protein apurinic/apyrimidinic endonuclease 1 (APE1), possesses anticancer activity, and can induce intracellular platinum accumulation and activate DNA damage response and apoptosis signaling.
体外研究
(In Vitro)

APE1-IN-2 (compound AP1) can strongly inhibit the growth of malignant cells, including Cisplatin-resistant cancer cells, with up to 18.11 times inhibition compared with Cisplatin (MS-E94993).
APE1-IN-2 (500 nM, 24 h) arrests the cell cycle in A549 and MCF7 cells.
APE1-IN-2 (10 μM, 24 h) induces p53-dependent apoptosis in A549 cells.
APE1-IN-2 (0-250 μM, 72 h) inhibits AP-cutting activity with an IC50 of 45.14 ± 17.37 μM.
APE1-IN-2 can directly inhibit the AP endonuclease activity of APE1, leading to an interruption of miRNA processing and upregulation of the tumor suppressor PTEN.

Cell Proliferation Assay

Cell Line: A549 (non-small cell lung cancer), MCF7 (breast cancer), U251 (glioblastoma), A375 (melanoma), PC3 (prostate cancer), and HEP-G2 (hepatocarcinoma) cell lines
Concentration:
Incubation Time: 72 h
Result: Demonstrated more potent antiproliferation effects than Cisplatin (MS-E94993), with IC50 of 0.45 ± 0.03, 0.43 ± 0.03, 4.70 ± 0.14, 0.39 ± 0.03, 5.65 ± 0.21, and 3.53 ± 0.31 μM in A549, MCF7, U251, A375, PC3, and HEP-G2 cell lines, respectively.

Cell Cycle Analysis

Cell Line: A549 and MCF7 cells
Concentration: 500 nM
Incubation Time: 24 h
Result: Induced the most severe S-phase arrest in A549 and MCF7 cells.

Cell Proliferation Assay

Cell Line: A549 cells
Concentration: 10 μM
Incubation Time: 24 h
Result: Caused apoptosis in approximately 38.7% (22.9% early apoptosis and 15.8% late apoptosis) of cancer cells.

Western Blot Analysis

Cell Line: A549 and HEK-293T cell lines
Concentration: 0, 16, 40, 100, 250 μM
Incubation Time: 72 h
Result: Significantly increased the level of p53 by 2.09 ± 0.51-fold. Slightly raised the levels of p53, γH2A.X, and cl.PARP in HEK-293T. Inhibited AP-cutting activity with an IC50 value of 45.14 ± 17.37 μM.
体内研究
(In Vivo)

APE1-IN-2 (compound AP1) (2 mg/kg, IP, once every 3 days for 15 days) exhibits an antitumor effect on the A549 xenograft model.

Animal Model: BALB/c nude mice (5 week-old, female, 16 ± 2 g of body weight bearing A549 xenograft tumors)
Dosage: 2 mg/kg
Administration: IP, once every 3 days for 15 days
Result: Exhibited a 3.86-fold xenograft tumor inhibitory activity compared to Cisplatin. Did not significantly alter the body weight of mice, improving its sufficient safety.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 522.21
分子式 C9H12Cl2N4O5Pt
CAS No. 2923433-95-6

储存&溶解度

溶解度信息
DMSO: Soluble, DMSO inactivates the activity of APE1-IN-2.
储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础